Peptide library8 min
GLP-1 medicines in the UAE
What GLP-1 medicines are, why they need medical supervision, and how UAE readers can avoid unsafe or fake products.
Each topic separates approved use from experimentation, human outcomes from laboratory findings, and evidence from marketing.
What GLP-1 medicines are, why they need medical supervision, and how UAE readers can avoid unsafe or fake products.
What semaglutide is, why the exact brand and indication matter, and how UAE readers can check supply safety.
Understand tirzepatide, product-specific approval, clinical supervision, and how to avoid unsafe or unverified supply.
What human studies suggest about oral collagen peptides and how to evaluate supplement claims in the UAE.
What is known about topical GHK-Cu, where evidence remains limited, and how to assess skincare claims.
A practical guide to cosmetic peptide serums, formulation evidence, claim language, and realistic expectations.
A cautious review of BPC-157, the dominance of animal research, lack of approved human use, and athlete considerations.
Why TB-500 marketing should not be confused with established human treatment evidence or approved medicine supply.
An evidence-focused explanation of CJC-1295, experimental status, growth-hormone pathway risks, and anti-doping concerns.
What consumers should know about ipamorelin marketing, limited evidence, unapproved products, and anti-doping risk.
Why injury recovery requires a diagnosis and rehabilitation plan, and why experimental peptide claims often overreach.
How to evaluate longevity and anti-ageing peptide claims without confusing biomarkers, cosmetic effects, and proven health outcomes.